{"classes":[{"categories":[{"measurements":[{"groupId":"OG000","spread":"0.3","value":"40.2"},{"groupId":"OG001","spread":"0.3","value":"41.0"}]}]}],"denoms":[{"counts":[{"groupId":"OG000","value":"205"},{"groupId":"OG001","value":"184"}],"units":"Participants"}],"description":"Patient reported peripheral neuropathy symptoms was measured with the Functional Assessment of Cancer Therapy/Gynecologic Oncology Group - neurotoxicity subscale (short version) (FACT/GOG-Ntx subscale). The FACT/GOG-Ntx subscale contains 11 items. Each item was scored using a 5-point scale (0=not at all; 1=a little bit; 2=somewhat; 3=quite a bit; 4=very much). . The Ntx score ranges 0-44 with a large score suggesting less peripheral neuropathy symptoms. Quality of Life was analyzed across cohorts since disease site was considered independent of Quality of Life.","dispersionType":"Standard Error","groups":[{"description":"Patients receive paclitaxel IV over 3 hours followed by carboplatin IV over 30-60 minutes on day 1.\n\nCarboplatin: Given IV\n\nPaclitaxel: Given IV\n\nQuality-of-Life Assessment: Ancillary studies","id":"OG000","title":"Regimen I - Uterine and Non-Uterine Subjects"},{"description":"Patients receive ifosfamide IV over 1 hour on days 1-3 followed by paclitaxel as in Arm I.\n\nIfosfamide: Given IV\n\nPaclitaxel: Given IV\n\nQuality-of-Life Assessment: Ancillary studies","id":"OG001","title":"Regimen II - Uterine and Non-Uterine Subjects"}],"paramType":"MEAN","populationDescription":"Subjects who provided baseline assessment","reportingStatus":"POSTED","timeFrame":"Baseline (Pre cycle 1)","title":"Patient Reported Peripheral Neuropathy Symptoms - Baseline","type":"SECONDARY","unitOfMeasure":"units on a scale-baseline"}